AU2005244483B2 - Essential fatty acids in the prevention and/or treatment of depression in patients with coronary heart or artery disease - Google Patents

Essential fatty acids in the prevention and/or treatment of depression in patients with coronary heart or artery disease Download PDF

Info

Publication number
AU2005244483B2
AU2005244483B2 AU2005244483A AU2005244483A AU2005244483B2 AU 2005244483 B2 AU2005244483 B2 AU 2005244483B2 AU 2005244483 A AU2005244483 A AU 2005244483A AU 2005244483 A AU2005244483 A AU 2005244483A AU 2005244483 B2 AU2005244483 B2 AU 2005244483B2
Authority
AU
Australia
Prior art keywords
ethyl ester
acid ethyl
mixture
high concentration
epa
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2005244483A
Other languages
English (en)
Other versions
AU2005244483A1 (en
Inventor
Rainer Oelze
Cees-Nico Verboom
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abbott Laboratories GmbH
Original Assignee
Abbott Laboratories GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Laboratories GmbH filed Critical Abbott Laboratories GmbH
Publication of AU2005244483A1 publication Critical patent/AU2005244483A1/en
Application granted granted Critical
Publication of AU2005244483B2 publication Critical patent/AU2005244483B2/en
Assigned to ABBOTT PRODUCTS GMBH reassignment ABBOTT PRODUCTS GMBH Request to Amend Deed and Register Assignors: SOLVAY PHARMACEUTICALS GMBH
Assigned to ABBOTT LABORATORIES GMBH reassignment ABBOTT LABORATORIES GMBH Request for Assignment Assignors: ABBOTT PRODUCTS GMBH
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2005244483A 2004-04-16 2005-04-15 Essential fatty acids in the prevention and/or treatment of depression in patients with coronary heart or artery disease Ceased AU2005244483B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP04101578.5 2004-04-16
EP04101578 2004-04-16
PCT/EP2005/004031 WO2005110393A1 (en) 2004-04-16 2005-04-15 Essential fatty acids in the prevention and/or treatment of depression in patients with coronary heart or artery disease

Publications (2)

Publication Number Publication Date
AU2005244483A1 AU2005244483A1 (en) 2005-11-24
AU2005244483B2 true AU2005244483B2 (en) 2011-06-09

Family

ID=34928968

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2005244483A Ceased AU2005244483B2 (en) 2004-04-16 2005-04-15 Essential fatty acids in the prevention and/or treatment of depression in patients with coronary heart or artery disease

Country Status (12)

Country Link
EP (1) EP1765319A1 (https=)
JP (1) JP2007532605A (https=)
CN (1) CN1942180A (https=)
AU (1) AU2005244483B2 (https=)
BR (1) BRPI0509878A (https=)
CA (1) CA2504280A1 (https=)
IL (1) IL178300A0 (https=)
MX (1) MX291518B (https=)
RU (1) RU2387448C2 (https=)
UA (1) UA94693C2 (https=)
WO (1) WO2005110393A1 (https=)
ZA (1) ZA200607794B (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2421909A (en) * 2004-12-23 2006-07-12 Laxdale Ltd Pharmaceutical compositions comprising EPA and methods of use
ITMI20100961A1 (it) * 2010-05-27 2011-11-28 Erredue Spa Miscele ricche in esteri di acidi grassi omega-3, loro composizioni e loro processo di preparazione

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998048788A1 (en) * 1997-04-29 1998-11-05 Scotia Holdings Plc Treatment of depression and anxiety using docosahexaenoic acid or natural antioxidants
IT1308613B1 (it) * 1999-02-17 2002-01-09 Pharmacia & Upjohn Spa Acidi grassi essenziali nella prevenzione di eventi cardiovascolari.
GB9916536D0 (en) * 1999-07-14 1999-09-15 Scarista Limited Nutritional or pharmaceutical compositions
ATE291910T1 (de) * 2001-05-30 2005-04-15 Laxdale Ltd Verwendung von coenzym q (ubiquinone) und eikosapentaensäure (epa) für die behandlung von non-hodgkin's lymphoma und psychiatrischen oder neurologischen erkrankungen

Also Published As

Publication number Publication date
UA94693C2 (ru) 2011-06-10
CN1942180A (zh) 2007-04-04
AU2005244483A1 (en) 2005-11-24
RU2387448C2 (ru) 2010-04-27
CA2504280A1 (en) 2005-10-16
MX291518B (es) 2011-10-31
JP2007532605A (ja) 2007-11-15
RU2006140277A (ru) 2008-05-27
ZA200607794B (en) 2008-05-28
BRPI0509878A (pt) 2007-10-16
WO2005110393A1 (en) 2005-11-24
IL178300A0 (en) 2007-02-11
MXPA06011940A (es) 2006-12-15
EP1765319A1 (en) 2007-03-28

Similar Documents

Publication Publication Date Title
CA2362271C (en) Essential fatty acids in the prevention of cardiovascular events
AU2004216856A1 (en) Use of omega-3-fatty acids in the treatment of diabetic patients
AU2021201865A1 (en) Omega-3 pentaenoic acid compositions and methods of use
EP2968246A1 (en) Omega-3 pentaenoic acid compositions and methods of use
US20040235948A1 (en) Treatment of diabetic patients with omega-3-fatty acids
US8114906B2 (en) Essential fatty acids in the treatment and/or inhibition of depression in patients with coronary heart or artery disease
AU2005244483B2 (en) Essential fatty acids in the prevention and/or treatment of depression in patients with coronary heart or artery disease
JP2007532605A5 (https=)
HK1099700A (en) Essential fatty acids in the prevention and/or treatment of depression in patients with coronary heart or artery disease
JPH08310948A (ja) 抗脱毛症剤

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE PATENTEE NAME FROM SOLVAY PHARMACEUTICALS GMBH TO ABBOTT PRODUCTS GMBH .

PC Assignment registered

Owner name: ABBOTT LABORATORIES GMBH

Free format text: FORMER OWNER WAS: ABBOTT PRODUCTS GMBH

MK14 Patent ceased section 143(a) (annual fees not paid) or expired